These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19081868)

  • 1. Bone metastases and lung cancer recurrence on (99m)Tc-depreotide imaging.
    Meristoudis G; Ilias I; Batsakis C; Christakopoulou J
    Hell J Nucl Med; 2008; 11(3):185-6, author reply 186. PubMed ID: 19081868
    [No Abstract]   [Full Text] [Related]  

  • 2. Soft tissue metastases and lung cancer recurrence detected by Tc-99m depreotide scintigraphy.
    Miliziano JS; Bradley YC
    Clin Nucl Med; 2002 Jun; 27(6):410-2. PubMed ID: 12045431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide.
    Menda Y; Kahn D
    Semin Nucl Med; 2002 Apr; 32(2):92-6. PubMed ID: 11965604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake of depreotide in a patient with lung cancer and bone metastases.
    Gao Z; Biersack HJ; Bucerius J
    Clin Nucl Med; 2005 Jan; 30(1):60-1. PubMed ID: 15604979
    [No Abstract]   [Full Text] [Related]  

  • 5. Contribution of (99m)Tc-depreotide (Neospect) scintigraphy in lung cancer staging.
    Karathanos E; Datseris I; Vlontzou E; Zisimopoulos A; Georgiou E
    J BUON; 2010; 15(1):147-52. PubMed ID: 20414943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative assessment of 99mTc-depreotide uptake in patients with non-small-cell lung cancer: immunohistochemical correlations.
    Herlin G; Kölbeck KG; Menzel PL; Svensson L; Aspelin P; Capitanio A; Axelsson R
    Acta Radiol; 2009 Oct; 50(8):902-8. PubMed ID: 19707908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 99mTc-depreotide scintigraphy of bone lesions in patients with lung cancer.
    Mena E; Camacho V; Estorch M; Fuertes J; Flotats A; Carrió I
    Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1399-404. PubMed ID: 15221296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of non-small cell lung cancer viability and necrosis with three radiopharmaceuticals.
    Sobic-Saranovic D; Pavlovic S; Jovanovic D; Nebojsa K; Todorovic-Tirnanic M; Subotic D; Artiko V; Obradovic V
    Hell J Nucl Med; 2008; 11(1):16-20. PubMed ID: 18392221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tc-99m MDP uptake by adrenal metastases from nonsmall cell carcinoma of the lung.
    Ozülker T; Ozülker F; Ozpaçaci T; Ergür S; Mülazimoğlu M
    Clin Nucl Med; 2005 Jul; 30(7):514-6. PubMed ID: 15965335
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of pentavalent Tc-99m DMSA scintigraphy in small cell and nonsmall cell lung cancers.
    Atasever T; Gündoğdu C; Vural G; Kapucu LO; Karalezli A; Unlü M
    Nuklearmedizin; 1997 Oct; 36(7):223-7. PubMed ID: 9394361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer.
    Hsia TC; Shen YY; Yen RF; Kao CH; Changlai SP
    Neoplasma; 2002; 49(4):267-71. PubMed ID: 12382027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrepant uptake between 111In-pentetreotide and 99mTc-MDP in bone metastases of small-cell lung cancer.
    Meristoudis G; Ilias I; Giannakopoulos V; Batsakis C; Christakopoulou J
    Hell J Nucl Med; 2009; 12(3):283-4. PubMed ID: 19936347
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of Tc-99m depreotide scintigraphy in the evaluation of solitary pulmonary nodules.
    Grewal RK; Dadparvar S; Yu JQ; Babaria CJ; Cavanaugh T; Sherman M; Jacobstein J
    Cancer J; 2002; 8(5):400-4. PubMed ID: 12416898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 99mTc-Depreotide chest SPECT demonstrates pulmonary metastases from renal cell carcinoma.
    Shih WJ; Romero RA; Timothy M; Milan PP
    J Nucl Med Technol; 2004 Mar; 32(1):19-21. PubMed ID: 14990670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. False negative F-18 FDG PET/CT in nonsmall cell lung cancer bone metastases.
    An YS; Yoon JK; Lee MH; Joh CW; Yoon SN
    Clin Nucl Med; 2005 Mar; 30(3):203-4. PubMed ID: 15722832
    [No Abstract]   [Full Text] [Related]  

  • 16. Technetium-99m tetrofosmin and technetium-99m sestamibi imaging of multiple metastases from differentiated thyroid carcinoma.
    Kosuda S; Yokoyama H; Katayama M; Yokokawa T; Kusano S; Yamamoto O
    Eur J Nucl Med; 1995 Oct; 22(10):1218-20. PubMed ID: 8542909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 99mTc depreotide scan compared with 99mTc-MDP bone scintigraphy for the detection of bone metastases and prediction of response to hormonal treatment in patients with breast cancer.
    Van Den Bossche B; D'haeninck E; De Winter F; Van Belle S; Dierckx RA; Van De Wiele C
    Nucl Med Commun; 2004 Aug; 25(8):787-92. PubMed ID: 15266172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
    Ak I; Sivrikoz MC; Entok E; Vardareli E
    Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative SPECT findings of Tc-99m depreotide, Tc-99m tetrofosmin, and Tl-201 chloride for bronchogenic carcinoma.
    Shih WJ; Bensadoun ES; Hirschowitz E; Kieffer V; Gross K
    Clin Nucl Med; 2002 Sep; 27(9):676-9. PubMed ID: 12192295
    [No Abstract]   [Full Text] [Related]  

  • 20. A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules.
    Blum J; Handmaker H; Lister-James J; Rinne N
    Chest; 2000 May; 117(5):1232-8. PubMed ID: 10807805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.